{"transactions":[{"id":2609826,"issuer":{"id":136487,"kind":"organization","name":"CHIASMA, INC","symbol":"CHMA"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-09T17:01:36.000Z","date":"2021-08-05","kind":"disposition_to_issuer","acquired":false,"shares":6770000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The filers are Stonepine Capital Management, LLC (\"Stonepine\"), Stonepine Capital, L.P. (the Partnership\"), Jon M. Plexico and Timothy P. Lynch. Stonepine is the general partner and investment adviser of the Partnership. Mr. Plexico and Mr. Lynch are Stonepine's managers and control persons. These securities are held directly by the Partnership for the benefit of its investors and are indirectly beneficially owned by Stonepine, as the general partner and investment adviser of the Partnership, and by Mr. Plexico and Mr. Lynch, as Stonepine's control persons. Stonepine is filing this Form 4 for itself and the other filers. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Each filer disclaims beneficial ownership of these securities except to the extent of that filer's pecuniary interest therein."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of May 4, 2021, by and among Chiasma, Inc. (the \"Company), Amryt Pharma plc (\"Parent\"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\") pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August 5, 2021 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company (each, a \"Share\") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.396 American Depositary Shares of Parent representing five ordinary shares of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of May 4, 2021, by and among Chiasma, Inc. (the \"Company), Amryt Pharma plc (\"Parent\"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\") pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August 5, 2021 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company (each, a \"Share\") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.396 American Depositary Shares of Parent representing five ordinary shares of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The filers are Stonepine Capital Management, LLC (\"Stonepine\"), Stonepine Capital, L.P. (the Partnership\"), Jon M. Plexico and Timothy P. Lynch. Stonepine is the general partner and investment adviser of the Partnership. Mr. Plexico and Mr. Lynch are Stonepine's managers and control persons. These securities are held directly by the Partnership for the benefit of its investors and are indirectly beneficially owned by Stonepine, as the general partner and investment adviser of the Partnership, and by Mr. Plexico and Mr. Lynch, as Stonepine's control persons. Stonepine is filing this Form 4 for itself and the other filers. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Each filer disclaims beneficial ownership of these securities except to the extent of that filer's pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-21-014770","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339469/000156761921014770/doc1.xml","form_type":"4"}},{"id":3344369,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-12T16:25:09.000Z","date":"2019-12-12","kind":"purchase","acquired":true,"shares":1000,"price":0.7,"value":700.0,"ownership":{"direct":true},"balance_after":3909207,"source":{"system":"sec-edgar","filing":"0001567619-19-022982","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/827809/000156761919022982/doc1.xml","form_type":"4"}},{"id":3344368,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-12T16:25:09.000Z","date":"2019-12-11","kind":"purchase","acquired":true,"shares":40,"price":0.69,"value":27.6,"ownership":{"direct":true},"balance_after":3908207,"source":{"system":"sec-edgar","filing":"0001567619-19-022982","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827809/000156761919022982/doc1.xml","form_type":"4"}},{"id":3344367,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-12T16:25:09.000Z","date":"2019-12-10","kind":"purchase","acquired":true,"shares":5202,"price":0.6916,"value":3597.7032,"ownership":{"direct":true},"balance_after":3908167,"source":{"system":"sec-edgar","filing":"0001567619-19-022982","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000156761919022982/doc1.xml","form_type":"4"}},{"id":3348898,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-09T16:51:39.000Z","date":"2019-12-09","kind":"purchase","acquired":true,"shares":4500,"price":0.7,"value":3150.0,"ownership":{"direct":true},"balance_after":3902965,"source":{"system":"sec-edgar","filing":"0001567619-19-022780","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/827809/000156761919022780/doc1.xml","form_type":"4"}},{"id":3348897,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-09T16:51:39.000Z","date":"2019-12-06","kind":"purchase","acquired":true,"shares":40,"price":0.7,"value":28.0,"ownership":{"direct":true},"balance_after":3898465,"source":{"system":"sec-edgar","filing":"0001567619-19-022780","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827809/000156761919022780/doc1.xml","form_type":"4"}},{"id":3348896,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-09T16:51:39.000Z","date":"2019-12-05","kind":"purchase","acquired":true,"shares":5160,"price":0.7,"value":3612.0,"ownership":{"direct":true},"balance_after":3898425,"source":{"system":"sec-edgar","filing":"0001567619-19-022780","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000156761919022780/doc1.xml","form_type":"4"}},{"id":3359407,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-26T17:24:12.000Z","date":"2019-11-22","kind":"purchase","acquired":true,"shares":89845,"price":0.7461,"value":67033.3545,"ownership":{"direct":true},"balance_after":3893265,"source":{"system":"sec-edgar","filing":"0001567619-19-022304","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000156761919022304/doc1.xml","form_type":"4"}},{"id":3393270,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-16T17:33:08.000Z","date":"2019-10-11","kind":"purchase","acquired":true,"shares":100000,"price":0.649,"value":64900.0,"ownership":{"direct":true},"balance_after":3803420,"source":{"system":"sec-edgar","filing":"0001567619-19-019667","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000156761919019667/doc1.xml","form_type":"4"}},{"id":3438543,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.0% Convertible Debenture due 2024","published_at":"2019-08-14T18:16:54.000Z","date":"2019-08-12","kind":"purchase","acquired":true,"price":2775000,"reported_value":2775000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Notwithstanding the number of shares reported in column 7, the Note may not be converted to the extent it would cause the Reporting Person and its affiliates to beneficially own more than 9.99% of the Stock."}],"derivative":{"exercise_price":3.25,"exercise_date":"2019-08-12","expiration_date":"2024-08-12","underlying":"Common Stock","underlying_shares":853847},"source":{"system":"sec-edgar","filing":"0001567619-19-017052","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000156761919017052/doc1.xml","form_type":"4"}},{"id":3438542,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2019-08-14T18:16:54.000Z","date":"2019-08-12","kind":"other","acquired":true,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the Warrant, except for a nominal exercise price of $0.001 per share of Stock, was pre-funded on or prior to the initial exercise date by the exchange described in footnote 1."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2019, the Reporting Person entered into a private transaction with the Issuer pursuant to which the Reporting Person exchanged 1,000,000 shares of the issuer's Common stock, par value $0.001 per share (the \"Stock\"), for a pre-funded warrant (the \"Warrant\") to purchase 1,000,000 shares of the Stock and purchased from the Issuer a 6.0% Convertible Debenture due 2024 (the \"Note\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2019, the Reporting Person entered into a private transaction with the Issuer pursuant to which the Reporting Person exchanged 1,000,000 shares of the issuer's Common stock, par value $0.001 per share (the \"Stock\"), for a pre-funded warrant (the \"Warrant\") to purchase 1,000,000 shares of the Stock and purchased from the Issuer a 6.0% Convertible Debenture due 2024 (the \"Note\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrant terminates if the Issuer enters into certain fundamental transactions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Notwithstanding the number of shares reported in column 7, the Warrant may not be exercised to the extent it would cause the Reporting Person and its affiliates to beneficially own more than 9.99% of the Stock."}],"balance_after":1,"derivative":{"exercise_date":"2019-08-12","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001567619-19-017052","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000156761919017052/doc1.xml","form_type":"4"}},{"id":3438541,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-14T18:16:54.000Z","date":"2019-08-12","kind":"other","acquired":false,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2019, the Reporting Person entered into a private transaction with the Issuer pursuant to which the Reporting Person exchanged 1,000,000 shares of the issuer's Common stock, par value $0.001 per share (the \"Stock\"), for a pre-funded warrant (the \"Warrant\") to purchase 1,000,000 shares of the Stock and purchased from the Issuer a 6.0% Convertible Debenture due 2024 (the \"Note\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2019, the Reporting Person entered into a private transaction with the Issuer pursuant to which the Reporting Person exchanged 1,000,000 shares of the issuer's Common stock, par value $0.001 per share (the \"Stock\"), for a pre-funded warrant (the \"Warrant\") to purchase 1,000,000 shares of the Stock and purchased from the Issuer a 6.0% Convertible Debenture due 2024 (the \"Note\")."}],"balance_after":1580518,"source":{"system":"sec-edgar","filing":"0001567619-19-017052","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000156761919017052/doc1.xml","form_type":"4"}},{"id":3715848,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-31T19:44:17.000Z","date":"2018-12-27","kind":"sale","acquired":false,"shares":250000,"price":3,"value":750000.0,"ownership":{"direct":true},"balance_after":2185426,"source":{"system":"sec-edgar","filing":"0001567619-18-008828","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000156761918008828/doc1.xml","form_type":"4"}},{"id":3716796,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-28T20:55:20.000Z","date":"2018-12-26","kind":"sale","acquired":false,"shares":500000,"price":3,"value":1500000.0,"ownership":{"direct":true},"balance_after":2435426,"source":{"system":"sec-edgar","filing":"0001567619-18-008814","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000156761918008814/doc1.xml","form_type":"4"}},{"id":3754446,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T17:32:48.000Z","date":"2018-11-21","kind":"purchase","acquired":true,"shares":3230,"price":3.605,"value":11644.15,"ownership":{"direct":true},"balance_after":2935426,"source":{"system":"sec-edgar","filing":"0001567619-18-006849","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000156761918006849/doc1.xml","form_type":"4"}},{"id":3754445,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T17:32:48.000Z","date":"2018-11-19","kind":"purchase","acquired":true,"shares":54200,"price":3.4,"value":184280.0,"ownership":{"direct":true},"balance_after":2932196,"source":{"system":"sec-edgar","filing":"0001567619-18-006849","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000156761918006849/doc1.xml","form_type":"4"}},{"id":3772352,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-06T16:22:04.000Z","date":"2018-11-02","kind":"purchase","acquired":true,"shares":300000,"price":5,"value":1500000.0,"ownership":{"direct":true},"balance_after":2877996,"source":{"system":"sec-edgar","filing":"0001567619-18-005171","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000156761918005171/doc1.xml","form_type":"4"}},{"id":4110873,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T17:33:58.000Z","date":"2018-01-03","kind":"purchase","acquired":true,"shares":6339,"price":5.7826,"value":36655.9014,"ownership":{"direct":true},"balance_after":2577996,"source":{"system":"sec-edgar","filing":"0001140361-18-000522","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000114036118000522/doc1.xml","form_type":"4"}},{"id":4110872,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T17:33:58.000Z","date":"2018-01-02","kind":"purchase","acquired":true,"shares":11343,"price":5.7269,"value":64960.2267,"ownership":{"direct":true},"balance_after":2571657,"source":{"system":"sec-edgar","filing":"0001140361-18-000522","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000114036118000522/doc1.xml","form_type":"4"}},{"id":4110871,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T17:33:58.000Z","date":"2017-12-29","kind":"purchase","acquired":true,"shares":5163,"price":5.5621,"value":28717.1223,"ownership":{"direct":true},"balance_after":2560314,"source":{"system":"sec-edgar","filing":"0001140361-18-000522","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000114036118000522/doc1.xml","form_type":"4"}},{"id":4120037,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-28T17:03:51.000Z","date":"2017-12-26","kind":"purchase","acquired":true,"shares":5287,"price":5,"value":26435.0,"ownership":{"direct":true},"balance_after":2555151,"source":{"system":"sec-edgar","filing":"0001140361-17-047619","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000114036117047619/doc1.xml","form_type":"4"}},{"id":4122282,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-22T17:26:15.000Z","date":"2017-12-22","kind":"purchase","acquired":true,"shares":41399,"price":4.9968,"value":206862.5232,"ownership":{"direct":true},"balance_after":2549864,"source":{"system":"sec-edgar","filing":"0001140361-17-047231","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000114036117047231/doc1.xml","form_type":"4"}},{"id":4122281,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-22T17:26:15.000Z","date":"2017-12-21","kind":"purchase","acquired":true,"shares":98324,"price":4.9423,"value":485946.7052,"ownership":{"direct":true},"balance_after":2508465,"source":{"system":"sec-edgar","filing":"0001140361-17-047231","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000114036117047231/doc1.xml","form_type":"4"}},{"id":4122280,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-22T17:26:15.000Z","date":"2017-12-20","kind":"purchase","acquired":true,"shares":45434,"price":4.4969,"value":204312.1546,"ownership":{"direct":true},"balance_after":2410141,"source":{"system":"sec-edgar","filing":"0001140361-17-047231","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000114036117047231/doc1.xml","form_type":"4"}},{"id":4376916,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":55025,"kind":"organization","name":"Stonepine Capital Management, LLC","position":1,"cik":"0001440771","reported_name":"Stonepine Capital Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":2,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163178,"kind":"person","name":"Plexico Jon M","position":3,"cik":"0001462580","reported_name":"Plexico Jon M","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20798,"kind":"person","name":"LYNCH TIMOTHY P","position":4,"cik":"0001270925","reported_name":"LYNCH TIMOTHY P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-21T17:22:06.000Z","date":"2017-03-17","kind":"purchase","acquired":true,"shares":1250000,"price":4,"value":5000000.0,"ownership":{"direct":false,"nature":"See Notes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The filers (the \"Filers\") are  Stonepine Capital Management, LLC (the \"General Partner\"), Stonepine Capital, L.P.,  Jon M. Plexico and Timothy P. Lynch.  These securities are directly held by Stonepine Capital, L.P. (2,599,711 shares) and other limited partnerships (collectively, the \"Funds\") for the benefit of their investors.  The General Partner is the general partner and investment adviser of the Funds.  Mr. Plexico and Mr. Lynch are the General Partner's managers and may be deemed to have shared voting and investment power over the shares held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Filers disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.  Each of the General Partner, Mr. Plexico and Mr. Lynch disclaims beneficial ownership of these securities except to the extent of that person's beneficial ownership therein."}],"balance_after":3849711,"source":{"system":"sec-edgar","filing":"0001140361-17-012865","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000114036117012865/doc1.xml","form_type":"4"}},{"id":4537834,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible 2.0% Senior Notes","published_at":"2016-12-01T15:42:44.000Z","date":"2016-11-29","kind":"grant","acquired":true,"shares":24000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for an equal number of Convertible 2.0% Senior Notes of Aegerion Pharmaceuticals, Inc. (\"AEGR\") in connection with the merger on November 29, 2016 in which AEGR became an indirect wholly-owned subsidiary of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These notes do not expire, but mature on August 15, 2019, unless earlier repurchased or converted."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The filers (the \"Filers\") are Stonepine Capital, L.P. (the \"Fund\"), Stonepine Capital Management, LLC (the \"General Partner\"), Jon M. Plexico and Timothy P. Lynch. The General Partner is the general partner and investment adviser of the Fund. Mr. Plexico and Mr. Lynch are the General Partner's managers and control persons. These securities are held directly by the Fund for the benefit of its investors and are indirectly beneficially owned by the General Partner and Mr. Plexico and Mr. Lynch as the General Partner's control persons. The Fund is filing this Form 4 for itself and the other Filers."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Each Filer disclaims beneficial ownership of these securities except to the extent of that Filer's pecuniary interest therein."}],"balance_after":24000000,"derivative":{"exercise_price":40.147,"exercise_date":"2019-02-15","underlying":"Common Stock","underlying_shares":597799},"source":{"system":"sec-edgar","filing":"0001140361-16-088383","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000114036116088383/doc1.xml","form_type":"4"}},{"id":4602882,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-09-15T19:48:18.000Z","date":"2016-09-15","kind":"purchase","acquired":true,"shares":14928,"price":1.55,"value":23138.4,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The filers (the \"Filers\") are Stonepine Capital, L.P. (the \"Fund\"), Stonepine Capital Management, LLC (the \"General Partner\"), Jon M. Plexico and Timothy P. Lynch. The General Partner is the general partner and investment adviser of the Fund. Mr. Plexico and Mr. Lynch are the General Partner's managers and control persons. These securities are held directly by the Fund for the benefit of its investors and are indirectly beneficially owned by the General Partner and Mr. Plexico and Mr. Lynch as the General Partner's control persons. The Fund is filing this Form 4 for itself and the other Filers."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Each Filer disclaims beneficial ownership of these securities except to the extent of that Filer's pecuniary interest therein."}],"balance_after":5778496,"source":{"system":"sec-edgar","filing":"0001140361-16-079947","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/827809/000114036116079947/doc1.xml","form_type":"4"}},{"id":4602881,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-09-15T19:48:18.000Z","date":"2016-09-14","kind":"purchase","acquired":true,"shares":56864,"price":1.5523,"value":88269.9872,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The filers (the \"Filers\") are Stonepine Capital, L.P. (the \"Fund\"), Stonepine Capital Management, LLC (the \"General Partner\"), Jon M. Plexico and Timothy P. Lynch. The General Partner is the general partner and investment adviser of the Fund. Mr. Plexico and Mr. Lynch are the General Partner's managers and control persons. These securities are held directly by the Fund for the benefit of its investors and are indirectly beneficially owned by the General Partner and Mr. Plexico and Mr. Lynch as the General Partner's control persons. The Fund is filing this Form 4 for itself and the other Filers."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Each Filer disclaims beneficial ownership of these securities except to the extent of that Filer's pecuniary interest therein."}],"balance_after":5763568,"source":{"system":"sec-edgar","filing":"0001140361-16-079947","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827809/000114036116079947/doc1.xml","form_type":"4"}},{"id":4602880,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":136488,"kind":"organization","name":"STONEPINE CAPITAL, L.P.","position":1,"cik":"0001370042","reported_name":"STONEPINE CAPITAL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-09-15T19:48:18.000Z","date":"2016-09-13","kind":"purchase","acquired":true,"shares":61704,"price":1.5423,"value":95166.0792,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The filers (the \"Filers\") are Stonepine Capital, L.P. (the \"Fund\"), Stonepine Capital Management, LLC (the \"General Partner\"), Jon M. Plexico and Timothy P. Lynch. The General Partner is the general partner and investment adviser of the Fund. Mr. Plexico and Mr. Lynch are the General Partner's managers and control persons. These securities are held directly by the Fund for the benefit of its investors and are indirectly beneficially owned by the General Partner and Mr. Plexico and Mr. Lynch as the General Partner's control persons. The Fund is filing this Form 4 for itself and the other Filers."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Each Filer disclaims beneficial ownership of these securities except to the extent of that Filer's pecuniary interest therein."}],"balance_after":5706704,"source":{"system":"sec-edgar","filing":"0001140361-16-079947","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000114036116079947/doc1.xml","form_type":"4"}}]}